Phase 1/2 Study of TSHA-105 in SLC13A5 Citrate Transporter Disorder Initiated
A Phase 1/2 open-label study is underway to evaluate TSHA-105 for SLC13A5 Citrate Transporter Disorder.
Phase I
Neurology / Gene Therapy
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the Phase 1/2 study for TSHA-105 represents a significant advancement in the treatment of a niche genetic disorder, potentially positioning the company favorably within the gene therapy landscape. Monitoring the trial's progress is crucial, as successful outcomes could lead to increased interest and competition from other biotech firms.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results and safety data from the ongoing trial.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.